GT Biopharma Advances in Phase 1 Trial for Blood Cancers
GT Biopharma Inc. (NASDAQ: GTBP) is making notable strides in its Phase 1 trial for the drug candidate GTB-3650, aimed at treating relapsed or refractory CD33-expressing hematologic malignancies. Recent updates reveal that patient enrollment into the dose escalation cohorts is progressing as planned. The company successfully completed enrollment in the initial two cohorts, and patients in Cohort 3 have begun treatment without any reported dose-limiting toxicities or safety issues thus far.
Impressive Immune Activation Observed
One of the standout findings from the trial is the significant level of immune activation noted in multiple biomarkers, particularly in the first patient of Cohort 3. This response aligns with the observed heightened immune activity in the initial four patients treated in Cohorts 1 and 2. Such findings are encouraging as they suggest potential efficacy in managing blood cancers.
Continued Dosing Escalation Anticipated
As the trial advances through Cohort 3 with positive safety evaluations, the program will move towards higher doses of GTB-3650. This escalation is crucial for translating the current immune activation into measurable therapeutic outcomes for the patients involved.
Future Milestones for GTB-3650
The initiation of dosing for Cohort 4 is targeted for late 2025, with ongoing updates and results expected by the first quarter of 2026. The trial aims to explore the drug's safety, pharmacokinetics, and pharmacodynamics, along with observing the in vivo expansion of endogenous patient NK cells and its clinical activity. The Phase 1 protocol accommodates the evaluation of the drug in up to 14 patients, with participants receiving doses ranging from 1.25 µg/kg/day in the first cohort to 100 µg/kg/day in the seventh cohort.
A Look at the Trial's Design and Purpose
The dosing strategy for GTB-3650 involves administering the drug in two-week cycles: two weeks of treatment followed by two weeks off, up to a maximum duration of four months or based on clinical benefit. This design is pivotal in establishing a thorough understanding of both the drug's safety profile and its therapeutic potential.
Price Action Updates
As of the latest market activity, GTBP stock reflects a 5.11% increase, marking a trading price of $0.79 during pre-market hours. This uptick indicates investor interest coinciding with the trial's positive developments and reinforces the market's anticipation of further results.
Frequently Asked Questions
What is GTB-3650 developed for?
GTB-3650 is designed to treat relapsed or refractory CD33-expressing hematologic malignancies, particularly in the context of blood cancers.
How many patients are involved in the Phase 1 trial?
The trial allows for the evaluation of GTB-3650 in approximately 14 patients, two patients per cohort across seven cohorts.
What are the potential side effects of GTB-3650?
To date, there have been no reports of dose-limiting toxicities or safety concerns among the participants up to the current stage of the trial.
When is the next dosing cohort planned?
The initiation of dosing in Cohort 4 is planned by the end of 2025, with data updates expected in early 2026.
How has the stock performed recently?
GTBP stock recently observed an increase of 5.11%, with a trading price of $0.79, reflecting positive investor confidence in the trial's outcomes.
